OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

by · The Markets Daily

Equities researchers at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $4.06.

Read Our Latest Stock Analysis on OCX

OncoCyte Stock Performance

Shares of OncoCyte stock opened at $3.34 on Friday. The business has a 50 day moving average of $3.13 and a 200 day moving average of $2.93. OncoCyte has a 52 week low of $2.08 and a 52 week high of $4.34.

OncoCyte (NASDAQ:OCX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The company had revenue of $0.10 million during the quarter.

About OncoCyte

(Get Free Report)

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

Read More